MCID: SGN002
MIFTS: 43

Signet Ring Cell Adenocarcinoma

Categories: Cancer diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Signet Ring Cell Adenocarcinoma

MalaCards integrated aliases for Signet Ring Cell Adenocarcinoma:

Name: Signet Ring Cell Adenocarcinoma 11 14
Signet Ring Cell Carcinoma 11 16 75
Carcinoma, Signet Ring Cell 43 71
Carcinoma Signet Ring Cell 53
Signet Ring Carcinoma 11

Classifications:



External Ids:

Disease Ontology 11 DOID:3493
MeSH 43 D018279
NCIt 49 C3774
SNOMED-CT 68 189701002
UMLS 71 C0206696

Summaries for Signet Ring Cell Adenocarcinoma

Disease Ontology: 11 An adenocarcinoma that derives from epithelial cells originating in glandular tissue, which have signet ring appearance.

MalaCards based summary: Signet Ring Cell Adenocarcinoma, also known as signet ring cell carcinoma, is related to bladder signet ring cell adenocarcinoma and bile duct signet ring cell carcinoma. An important gene associated with Signet Ring Cell Adenocarcinoma is KRT7 (Keratin 7), and among its related pathways/superpathways are Disease and TCR Signaling (Qiagen). The drugs Irinotecan and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include colon, lymph node and breast, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

Wikipedia: 75 Signet ring cell carcinoma (SRCC) is a rare form of highly malignant adenocarcinoma that produces mucin.... more...

Related Diseases for Signet Ring Cell Adenocarcinoma

Diseases related to Signet Ring Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 704)
# Related Disease Score Top Affiliating Genes
1 bladder signet ring cell adenocarcinoma 33.3 KRT7 CDX2
2 bile duct signet ring cell carcinoma 33.1 KRT7 KRT20
3 gastric signet ring cell adenocarcinoma 33.0 PIP KRT7 CDX2 CDH1
4 gallbladder signet ring cell adenocarcinoma 32.8 KRT7 KRT20 CDX2 CDH1
5 krukenberg carcinoma 32.7 KRT7 KRT20 CEACAM5 CDX2
6 rectum signet ring adenocarcinoma 32.7 MLH1 CEACAM5
7 pancreatic signet ring cell adenocarcinoma 32.0 TP53 MUC6 MUC5AC MLH1 KRAS HRAS
8 diffuse gastric and lobular breast cancer syndrome 31.7 TP53 PDPN MUC6 MLH1 KRAS ERBB2
9 bladder adenocarcinoma 31.2 TP53 KRT7 KRT20 CEACAM5 CDX2
10 diffuse gastric cancer 31.0 TP53 PDPN MLH1 KRAS ERBB2 CDH1
11 neuroendocrine carcinoma 30.9 KRT7 KRT20 CHGA CDH1
12 linitis plastica 30.9 PIP KRT7 KRT20 ERBB2 CEACAM5 CDX2
13 bile duct cysts 30.7 KRT7 KRAS HRAS CEACAM5
14 mucoepidermoid carcinoma 30.7 MUC5AC MUC2 KRT7 CDH1
15 ampulla of vater benign neoplasm 30.7 KRAS HRAS CHGA
16 small cell carcinoma 30.7 TP53 KRT7 KRT20 CHGA CEACAM5
17 appendiceal neoplasm 30.6 KRT7 KRAS HRAS CHGA CEACAM5 CDX2
18 cystitis cystica 30.6 KRT7 KRT20 CDX2
19 papillary carcinoma 30.6 KRT7 KRT20 ERBB2 CHGA CDH1
20 endodermal sinus tumor 30.6 KRT7 CHGA CEACAM5
21 exanthem 30.6 KRAS HRAS ERBB2
22 acute cholangitis 30.6 MUC6 MUC5AC CEACAM5
23 eyelid carcinoma 30.5 PIP KRT7 KRT20
24 intestinal obstruction 30.5 KRT7 KRT20 CEACAM5 CDX2
25 merkel cell carcinoma 30.5 KRT7 KRT20 CHGA
26 neuroendocrine tumor 30.5 KRT20 CHGA CDX2 CDH1
27 hepatoid adenocarcinoma 30.5 MUC6 KRT7 CEACAM5 CDX2
28 breast lobular carcinoma 30.5 TP53 PIP KRT7 ERBB2 CDH1
29 cystitis 30.5 TP53 KRT7 KRT20 CDH1
30 solid adenocarcinoma with mucin production 30.5 MUC6 MUC5AC KRT7 CHGA
31 vaginal cancer 30.5 TP53 KRT7 HRAS
32 glandular cystitis 30.5 TP53 KRT7 KRT20 CDX2
33 benign mesothelioma 30.4 PDPN KRT7 KRT20 CEACAM5
34 colon adenocarcinoma 30.4 TP53 MLH1 KRT20 KRAS HRAS CEACAM5
35 lymphangitis 30.4 PDPN KRT7 ERBB2 CEACAM5
36 appendix adenocarcinoma 30.4 TP53 KRT7 KRT20 KRAS HRAS CHGA
37 bladder urachal carcinoma 30.4 KRT7 KRAS HRAS CDX2
38 sweat gland cancer 30.4 TP53 PIP KRT7 KRT20 ERBB2 CEACAM5
39 esophagus adenocarcinoma 30.4 TP53 ERBB2 CDX2 CDH1
40 neurofibromatosis, type i 30.4 TP53 MLH1 KRAS HRAS
41 neurofibromatosis 30.4 TP53 MLH1 KRAS HRAS
42 adenosquamous carcinoma 30.3 MUC5AC KRT7 KRT20 KRAS HRAS CHGA
43 tubular adenocarcinoma 30.3 MUC6 MUC5AC MUC2 KRT7 KRT20 ERBB2
44 cholecystitis 30.3 TP53 MUC6 MUC5AC CDH1
45 paget disease, extramammary 30.3 PIP MUC5AC KRT7 KRT20 ERBB2 CEACAM5
46 thyroid gland follicular carcinoma 30.3 TP53 KRT7 HRAS CDH1
47 myoma 30.3 TP53 KRAS CEACAM5
48 papilloma 30.3 TP53 KRT7 KRT20 KRAS ERBB2 CDH1
49 endometrial adenocarcinoma 30.3 TP53 MLH1 KRT7 KRAS
50 thymus cancer 30.3 TP53 KRT7 HRAS ERBB2

Graphical network of the top 20 diseases related to Signet Ring Cell Adenocarcinoma:



Diseases related to Signet Ring Cell Adenocarcinoma

Symptoms & Phenotypes for Signet Ring Cell Adenocarcinoma

GenomeRNAi Phenotypes related to Signet Ring Cell Adenocarcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 ARFIP2 CDH1 CHGA HRAS KRAS KRT7

MGI Mouse Phenotypes related to Signet Ring Cell Adenocarcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.21 CDH1 CDX2 CEACAM5 CHGA EPPIN ERBB2
2 growth/size/body region MP:0005378 10.13 CDH1 CDX2 CEACAM5 CHGA EPPIN ERBB2
3 neoplasm MP:0002006 10.1 CDH1 CDX2 CEACAM5 ERBB2 HRAS KRAS
4 endocrine/exocrine gland MP:0005379 10.07 CDH1 CDX2 CEACAM5 CHGA EPPIN ERBB2
5 digestive/alimentary MP:0005381 9.97 CDH1 CDX2 CEACAM5 EPPIN ERBB2 HRAS
6 cardiovascular system MP:0005385 9.77 ARFIP2 CDH1 CDX2 CEACAM5 CHGA EPPIN
7 integument MP:0010771 9.28 CDH1 EPPIN ERBB2 HRAS KRAS MLH1

Drugs & Therapeutics for Signet Ring Cell Adenocarcinoma

Drugs for Signet Ring Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
2
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
3
Fluorouracil Approved Phase 3 51-21-8 3385
4
Bevacizumab Approved, Investigational Phase 3 216974-75-3 135329020
5
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
6
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 11947679 6857599
7
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
8
Camptothecin Experimental Phase 3 7689-03-4 24360
9
Rivoceranib Investigational Phase 3 811803-05-1 11315474
10 topoisomerase I inhibitors Phase 3
11 Formyltetrahydrofolates Phase 3
12 Tetrahydrofolates Phase 3
13 Antineoplastic Agents, Immunological Phase 3
14 Immunoglobulins, Intravenous Phase 3
15 Immunoglobulins Phase 3
16 Antibodies, Monoclonal Phase 3
17 Antibodies Phase 3
18 Immunologic Factors Phase 3
19 Cola Phase 3
20 Vitamins Phase 3
21 Folate Phase 3
22 Vitamin B9 Phase 3
23 Trace Elements Phase 3
24 Vitamin B Complex Phase 3
25 Antidotes Phase 3
26 Calcium, Dietary Phase 3
27 Immunosuppressive Agents Phase 3
28 Micronutrients Phase 3
29 Protective Agents Phase 3
30 Hormones Phase 3
31 Immunoglobulin G Phase 3
32 Angiogenesis Inhibitors Phase 3
33 Hematinics Phase 3
34 Endothelial Growth Factors Phase 3
35 Mitogens Phase 3
36 Antimetabolites Phase 3
37 Protein Kinase Inhibitors Phase 3
38
Calcium Nutraceutical Phase 3 7440-70-2 271
39
Nivolumab Approved Phase 2 946414-94-4
40
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
41
Turmeric Approved, Experimental, Investigational Phase 2
42
Curcumin Approved, Investigational Phase 2 458-37-7, 84765-67-3 969516
43 Immune Checkpoint Inhibitors Phase 2
44 Antirheumatic Agents Phase 2
45 Anti-Inflammatory Agents, Non-Steroidal Phase 2
46 Turmeric extract Phase 2
47 Anti-Inflammatory Agents Phase 2
48 Analgesics, Non-Narcotic Phase 2
49 Analgesics Phase 2
50
Cetuximab Approved Phase 1 205923-56-4

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients With Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil Completed NCT00068692 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin;Irinotecan
2 A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers Active, not recruiting NCT00217737 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin
3 A Randomized, Multicenter, Controlled Study of XELOX (Oxaliplatin With Capecitabine) Combined With Apatinib Versus XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma With D2 Dissection. Not yet recruiting NCT03355612 Phase 3 Apatinib;XELOX
4 A Phase 2 Study of MK-2206 in Previously Treated Metastatic Colorectal Cancer Patients Enriched for PTEN Loss and PIK3CA Mutation Completed NCT01802320 Phase 2 Akt Inhibitor MK2206
5 A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors Recruiting NCT02978625 Phase 2
6 METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin Recruiting NCT05504252 Phase 2 Nivolumab;Oxaliplatin
7 A Randomized Double Blinded Study of Curcumin With Pre-operative Capecitabine and Radiation Therapy Followed by Surgery for Rectal Cancer Terminated NCT00745134 Phase 2 Capecitabine
8 Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer Terminated NCT01198535 Phase 1 Gamma-Secretase Inhibitor RO4929097
9 Has the Quota of Signet Ring Cells an Influence on Prognosis and Treatment Strategy in the Upper GI Tract Adenocarcinomas? Completed NCT01249859

Search NIH Clinical Center for Signet Ring Cell Adenocarcinoma

Cochrane evidence based reviews: carcinoma, signet ring cell

Genetic Tests for Signet Ring Cell Adenocarcinoma

Anatomical Context for Signet Ring Cell Adenocarcinoma

Organs/tissues related to Signet Ring Cell Adenocarcinoma:

MalaCards : Colon, Lymph Node, Breast, Prostate, Skin, Bone Marrow, Appendix

Publications for Signet Ring Cell Adenocarcinoma

Articles related to Signet Ring Cell Adenocarcinoma:

(show top 50) (show all 2183)
# Title Authors PMID Year
1
Chromogranin A expression correlates with tumour cell type and prognosis in signet ring cell carcinoma of the stomach. 53 62
18269581 2008
2
Distinct expression patterns of E-cadherin and beta-catenin in signet ring cell carcinoma components of primary pulmonary adenocarcinoma. 53 62
16948518 2006
3
Primary cutaneous signet ring cell carcinoma expressing cytokeratin 20 immunoreactivity. 53 62
16488312 2006
4
Dynamic alteration of the E-cadherin/catenin complex during cell differentiation and invasion of undifferentiated-type gastric carcinomas. 53 62
15682444 2005
5
Molecular characteristics of eight gastric cancer cell lines established in Japan. 53 62
11107048 2000
6
The role of cytokeratins 20 and 7 and estrogen receptor analysis in separation of metastatic lobular carcinoma of the breast and metastatic signet ring cell carcinoma of the gastrointestinal tract. 53 62
11028811 2000
7
Gastric metastasis of mammary signet ring cell carcinoma--a differential diagnosis with primary gastric signet ring cell carcinoma. 53 62
9250925 1997
8
A case of small cell carcinoma of the stomach. 53 62
9058136 1997
9
E-cadherin gene mutations in signet ring cell carcinoma of the stomach. 53 62
8797891 1996
10
Marked elevation of plasma carcinoembryonic antigen and stomach carcinoma. 53 62
8640661 1996
11
Breast metastasis of signet ring cell carcinoma from the colon: a case report. 62
36451153 2022
12
Therapeutic plasma exchange in gastric signet ring cell carcinoma presenting as microangiopathic hemolytic anemia: A rare case report. 62
36125111 2022
13
Bilateral ovarian metastasis after laparoscopic right hemicolectomy for signet-ring cell carcinoma. 62
35780022 2022
14
Exceptional Variant with Distant Cutaneous Metastasis as the First Clinical Sign in Gastric Signet-Ring Carcinoma. 62
34786642 2022
15
Peritoneal metastatic mixed adenoneuroendocrine carcinoma treated with cytoreduction surgery and hyperthermic intraperitoneal chemotherapy: a case report. 62
36404497 2022
16
Pleural metastasis from pulmonary primary signet-ring squamous cell carcinoma. Case report and literature review. 62
36318823 2022
17
Epidemiology and prognostic analysis of patients with pancreatic signet ring cell carcinoma: a population-based study. 62
36384527 2022
18
The therapeutic efficacy of radical prostatectomy and external beam radiation therapy in patients with different pathological patterns of prostate cancer. 62
36376185 2022
19
Survival Outcomes and Clinicopathological Features in Inflammatory Bowel Disease-associated Colorectal Cancer: A Systematic Review and Meta-analysis. 62
34913897 2022
20
Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability‒High Colon Cancer. 62
35038827 2022
21
Clinical features and prognostic factors of esophageal signet ring cell carcinoma: construction and validation of a model based on the SEER database. 62
36388034 2022
22
Gastric Cancer After Helicobacter pylori Eradication for Nodular Gastritis in an Adolescent. 62
36381762 2022
23
Clinicopathological Characteristics of Advanced Epstein-Barr Virus-associated Gastric Cancer Highlighting Aberrant p53 Expression. 62
36191967 2022
24
Clinicopathological and molecular characterization of early gastric adenocarcinoma in Helicobacter pylori-uninfected patients: emphasis on differentiated gastric adenocarcinoma. 62
35939123 2022
25
Genomically stable gastric cancer characterized by hypomethylation in Wnt signal cascade. 62
36244328 2022
26
Superficial nonampullary duodenal epithelial tumor: a rare case with signet-ring cell carcinoma component diagnosed by magnifying endoscopy. 62
36216257 2022
27
Signet Ring Cell Carcinoma at the Ampulla of Vater: A Very Rare Diagnosis. 62
36407266 2022
28
Clinicopathological characteristics and prognosis of gastric signet ring cell carcinoma. 62
36312481 2022
29
Primary signet ring cell carcinoma of the appendix: An interesting case. 62
35595079 2022
30
Pathological Nodal Staging Score for Gastric Signet Ring Cell Carcinoma: A Clinical Tool of Adequate Nodal Staging. 62
36291978 2022
31
Colorectal signet-ring cell carcinoma treated with FOLFOX plus panitumumab. 62
36169041 2022
32
Primary signet-ring cell carcinoma of the cecum: A rare case report. 62
35973320 2022
33
Pathological and oncological outcomes of pylorus-preserving versus conventional distal gastrectomy in early gastric cancer: a systematic review and meta-analysis. 62
36153587 2022
34
Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy. 62
35715659 2022
35
Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model. 62
35661943 2022
36
Superiority of [68Ga]Ga-FAPI-04/[18F]FAPI-42 PET/CT to [18F]FDG PET/CT in delineating the primary tumor and peritoneal metastasis in initial gastric cancer. 62
35380229 2022
37
Microangiopathic Hemolytic Anemia Is a Late and Fatal Complication of Gastric Signet Ring Cell Carcinoma: A Systematic Review and Case-Control Study. 62
35589098 2022
38
Mucinous Proliferations of the Uterine Corpus: Comprehensive Appraisal of an Evolving Spectrum of Neoplasms. 62
35499137 2022
39
Immunohistochemical analysis of PD-L1 and tumor-infiltrating immune cells expression in the tumor microenvironment of primary signet ring cell carcinoma of the prostate. 62
35042311 2022
40
Risk factors for metachronous peritoneal carcinomatosis after radical resection for patients with nonmetastatic pT3-4 colon cancer. 62
35661159 2022
41
Colonic infiltration of chronic lymphocytic leukemia with Hodgkin Reed Sternberg-like cells. 62
35297262 2022
42
Signet-ring cell carcinoma of the appendix with ganglioneuromatosis: a case report. 62
35927360 2022
43
Clinical value and influencing factors of establishing stomach cancer organoids by endoscopic biopsy. 62
35987927 2022
44
Genomic analysis of an aggressive case with metastatic intrahepatic mucinous cholangiocarcinoma. 62
35699889 2022
45
Comparison of [68Ga]Ga-FAPI and [18F]FDG uptake in patients with gastric signet-ring-cell carcinoma: a multicenter retrospective study. 62
35976396 2022
46
Nerve invasion as an independent predictor of poor prognosis in gastric cancer after curative resection. 62
35984131 2022
47
Treatment outcomes of patients with involved resection margin after rectal cancer surgery: A nationwide population-based cohort study in South Korea. 62
34310853 2022
48
Surveillance of Russell body inflammation of the digestive tract: a case report and review of literature. 62
36002890 2022
49
Trends, clinicopathological features, surgical treatment patterns and prognoses of early-onset versus late-onset colorectal cancer: A retrospective cohort study on 34067 patients managed from 2000 to 2021 in a Chinese tertiary center. 62
35850466 2022
50
Endoscopic submucosal dissection for early signet ring cell gastric cancer: A systematic review and meta-analysis. 62
36051146 2022

Variations for Signet Ring Cell Adenocarcinoma

Expression for Signet Ring Cell Adenocarcinoma

Search GEO for disease gene expression data for Signet Ring Cell Adenocarcinoma.

Pathways for Signet Ring Cell Adenocarcinoma

Pathways related to Signet Ring Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.76 TP53 SRC MUC6 MUC5AC MLH1 KRAS
2
Show member pathways
12.85 TP53 SRC MLH1 KRAS HRAS ARFIP2
3
Show member pathways
12.71 TP53 KRAS HRAS CDH1 ARFIP2
4
Show member pathways
12.55 SRC MUC5AC MUC2 KRAS HRAS
5
Show member pathways
12.51 ERBB2 HRAS KRAS SRC TP53
6
Show member pathways
12.4 TP53 KRAS HRAS ERBB2
7
Show member pathways
12.38 TP53 KRAS HRAS ERBB2
8
Show member pathways
12.34 TP53 SRC HRAS ERBB2 CDH1
9
Show member pathways
12.32 KRAS HRAS ERBB2 CDH1 ARFIP2
10
Show member pathways
12.3 SRC MUC6 MUC5AC KRAS HRAS
11
Show member pathways
12.16 CEACAM5 HRAS KRAS SRC
12
Show member pathways
12.12 ERBB2 HRAS KRAS SRC TP53
13
Show member pathways
12.12 TP53 SRC KRAS HRAS ERBB2 CDH1
14
Show member pathways
12.12 TP53 SRC MLH1 KRAS HRAS ERBB2
15 12.11 TP53 KRAS HRAS CDH1
16
Show member pathways
11.99 SRC KRAS HRAS ERBB2
17 11.98 TP53 SRC MLH1 KRAS CDH1
18
Show member pathways
11.96 SRC KRAS HRAS ERBB2
19 11.94 SRC KRAS HRAS CDH1
20
Show member pathways
11.85 SRC KRAS HRAS
21
Show member pathways
11.85 SRC KRAS HRAS
22 11.79 TP53 KRAS HRAS ERBB2
23
Show member pathways
11.78 SRC KRAS HRAS
24 11.75 TP53 SRC HRAS
25
Show member pathways
11.72 TP53 KRAS HRAS
26 11.72 TP53 SRC KRAS
27 11.7 CDH1 CHGA HRAS KRAS SRC
28 11.67 CDH1 HRAS SRC
29 11.6 TP53 HRAS ERBB2
30
Show member pathways
11.59 SRC HRAS ARFIP2
31 11.57 TP53 KRAS HRAS ERBB2
32 11.47 SRC HRAS CDH1
33 11.38 SRC KRAS HRAS ERBB2
34 11.32 HRAS ERBB2 CDH1
35 11.15 KRAS HRAS ERBB2
36 10.99 HRAS KRAS SRC
37 10.93 SRC KRAS HRAS
38
Show member pathways
10.75 KRAS HRAS
39 10.7 TP53 SRC KRAS HRAS ERBB2 CDH1
40 10.65 TP53 CDH1

GO Terms for Signet Ring Cell Adenocarcinoma

Cellular components related to Signet Ring Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mucus layer GO:0070701 8.8 MUC5AC MUC2

Biological processes related to Signet Ring Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.28 TP53 SRC PIP KRAS HRAS ERBB2

Sources for Signet Ring Cell Adenocarcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....